Volume 19, Number 2—February 2013
Dispatch
Macrolide- and Rifampin-Resistant Rhodococcus equi on a Horse Breeding Farm, Kentucky, USA
Table 1
Year | No. foals born | No. (%) foals with lesions treated | No. foals tested | No. foals with positive R. equi culture | No. (%) foals with macrolide- and rifampin-resistant R. equi |
---|---|---|---|---|---|
2001 | 95 | 30 (32) | 30 | 30 | 0 |
2002 | 117 | 53 (45) | 0 | NA | NA |
2003 | 148 | 58 (32) | 2 | ? | ? |
2004 | 181 | 88 (49) | 28 | 19 | 0 |
2005 | 168 | 70 (42) | 30 | ? | ? |
2006 | 170 | 42 (41) | 5 | 2 | 0 |
2007 | 181 | 93 (51) | 4 | ? | ? |
2008 | 171 | 52 (30) | 21 | 16 | 4 (25)† |
2009 | 162 | 50 (31) | 30 | 22 | 5 (23)† |
2010 | 138 | 45 (33) | 28 | 22 | 9 (41)† |
2011 | 132 | 24 (18) | 27 | 25 | 9 (36)† |
*NA, not applicable; ?, data missing from farm records.
†Includes pretreatment and posttreatment isolates.
1Current affiliation: Kalon Biotherapeutics LLC, College Station, Texas, USA.
Page created: January 22, 2013
Page updated: January 22, 2013
Page reviewed: January 22, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.